Castle Biosciences Corp - רווח נקי למניה (EPS TTM) CSTL

Castle Biosciences generates revenue through the implementation of advanced genetic tests for assessing recurrences of skin neoplasms. The large-scale adoption of these studies in clinics ensures sustainable growth for the company. Strong pricing power is supported by the critical importance of diagnostics for melanoma therapy. Analyzing the annual EPS TTM chart on GURU.Markets, we find that the value is fixed at -81.70.

Cost optimization through cloud data analysis and logistics outsourcing allows Castle Biosciences (CSTL) to scale operational efficiency. The trend of this profit, calculated as the percentage change in rolling annual EPS, determines the real cost of capital under tight Fed policy, making the current TTM EPS annual growth value a key indicator for identifying undervalued assets.